Emergent Biosolutions (EBS) stock
Members see every stock ranked and every check behind each score, live.
Why EBS scores 1
Below AverageChoppy, 4 of 13 possible checks firingWhat the Quality Score means
- +4Momentum traits 4 firing right now, of 13 possible, one point each
- −2Long-term trend below a falling 200-day, down over one year
- Profit subtracts
What's next
Expected to report Wed Oct 28, after the close
After its last 4 reports it closed -4.2% on average, higher 2 of 4 times.
What would turn EBS's score around: 6 things, for members
Here is what members see.
Every stock gets a card like this one, and a page with its price in real time, every line of its score, the chart, and its filings.
EBS has 4 of a possible 13 checks firing
14 checks. Two are opposites (heavy volume and quiet volume), so at most 13 are on at once. One per group is shown here.
How EBS ranks in Biotech
EBS is #100 of 260 by Quality Score. The top three are shown with their scores, and the rest by name.
TGTX8/1319
RGEN7/1319
HALO7/1319
EXELOpen for its score
ONCOpen for its score
EBS4/131
When does EBS report, and what happens after?
Expected to report Wed Oct 28, after the close (in 30 days). Not yet confirmed by the company.
| Reported | When | Gap | Reaction | 5 sessions |
|---|---|---|---|---|
| Aug 5, 2026After close | After close | -21.1% | -29.6% | -39.7% |
| Apr 30, 2026After close | After close | +9.2% | +2.9% | +10.9% |
| Feb 26, 2026After close | After close | -26.1% | -26.6% | -24.0% |
| Oct 29, 2025After close | After close | +15.5% | +36.6% | +10.0% |
About Emergent Biosolutions
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.
Every line of the score, on every stock.
- Real-time prices, no delay
- Every line of EBS's score, with the points and the reason
- All 14 checks on EBS and on all 2,950 stocks
- Every stock ranked, with the chart
- Every filing, and optional alerts on EBS
Straight answers.
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Members, trial included, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Where does the data come from?
Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week traits rest on real history. Options flow is not part of the product.
What does it cost?
One plan with everything in it: $29 a month, $69 for three months, or $249 a year. You pick the billing period when the trial ends, and payments go through Stripe, so Breakaway never sees your card.
Is this investment advice?
No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.